These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 25860797)

  • 1. An individual patient data meta-analysis on characteristics, treatments and outcomes of glioblastoma/ gliosarcoma patients with metastases outside of the central nervous system.
    Pietschmann S; von Bueren AO; Kerber MJ; Baumert BG; Kortmann RD; Müller K
    PLoS One; 2015; 10(4):e0121592. PubMed ID: 25860797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An individual patient data meta-analysis on characteristics, treatments and outcomes of the glioblastoma/gliosarcoma patients with central nervous system metastases reported in literature until 2013.
    Pietschmann S; von Bueren AO; Henke G; Kerber MJ; Kortmann RD; Müller K
    J Neurooncol; 2014 Dec; 120(3):451-7. PubMed ID: 25160993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and survival of patients harboring histological variants of glioblastoma.
    Ortega A; Nuño M; Walia S; Mukherjee D; Black KL; Patil CG
    J Clin Neurosci; 2014 Oct; 21(10):1709-13. PubMed ID: 24980627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results.
    Galanis E; Buckner JC; Dinapoli RP; Scheithauer BW; Jenkins RB; Wang CH; O'Fallon JR; Farr G
    J Neurosurg; 1998 Sep; 89(3):425-30. PubMed ID: 9724117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary gliosarcoma with extra-cranial metastases: a report and review of the literature.
    Dawar R; Fabiano AJ; Qiu J; Khushalani NI
    Clin Neurol Neurosurg; 2013 Apr; 115(4):375-80. PubMed ID: 22795300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
    Han SJ; Yang I; Otero JJ; Ahn BJ; Tihan T; McDermott MW; Berger MS; Chang SM; Parsa AT
    J Neurosurg; 2010 May; 112(5):990-6. PubMed ID: 19817543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature.
    Anghileri E; Castiglione M; Nunziata R; Boffano C; Nazzi V; Acerbi F; Finocchiaro G; Eoli M
    Neurosurg Rev; 2016 Jan; 39(1):37-45; discussion 45-6. PubMed ID: 26212701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy.
    Damodaran O; van Heerden J; Nowak AK; Bynevelt M; McDonald K; Marsh J; Lee G
    J Clin Neurosci; 2014 Mar; 21(3):478-81. PubMed ID: 24332268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review on the Characteristics, Treatments and Outcomes of the Patients with Primary Spinal Glioblastomas or Gliosarcomas Reported in Literature until March 2015.
    Beyer S; von Bueren AO; Klautke G; Guckenberger M; Kortmann RD; Pietschmann S; Müller K
    PLoS One; 2016; 11(2):e0148312. PubMed ID: 26859136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative epidemiology of gliosarcoma and glioblastoma and the impact of Race on overall survival: A systematic literature review.
    Gerges C; Elder T; Penuela M; Rossetti N; Maynard M; Jeong S; Wright CH; Wright J; Zhou X; Burant C; Sajatovic M; Hodges T
    Clin Neurol Neurosurg; 2020 Aug; 195():106054. PubMed ID: 32650210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
    Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
    Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gliosarcoma: an audit from a single institution in India of 24 post-irradiated cases over 15 years.
    Kumar P; Singh S; Kumar P; Krishnani N; Datta NR
    J Cancer Res Ther; 2008; 4(4):164-8. PubMed ID: 19052388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The natural history of extracranial metastasis from glioblastoma multiforme.
    Lun M; Lok E; Gautam S; Wu E; Wong ET
    J Neurooncol; 2011 Nov; 105(2):261-73. PubMed ID: 21512826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
    Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
    Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gliosarcoma: a clinical study.
    Lutterbach J; Guttenberger R; Pagenstecher A
    Radiother Oncol; 2001 Oct; 61(1):57-64. PubMed ID: 11578729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Giant cell glioblastoma multiforme: report of a case with prolonged survival and transformation to gliosarcoma.
    Deb P; Sharma MC; Chander B; Mahapatra AK; Sarkar C
    Childs Nerv Syst; 2006 Mar; 22(3):314-9. PubMed ID: 16133270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gliosarcoma: a rare variant of glioblastoma multiforme.
    Rizvi S; Asghar AH; Mehboob J
    J Pak Med Assoc; 2010 Sep; 60(9):773-5. PubMed ID: 21381591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
    Vordermark D; Ruprecht K; Rieckmann P; Roggendorf W; Vince GH; Warmuth-Metz M; Kölbl O; Flentje M
    BMC Cancer; 2006 Oct; 6():247. PubMed ID: 17049083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extra-CNS metastasis from glioblastoma: a rare clinical entity.
    Awan M; Liu S; Sahgal A; Das S; Chao ST; Chang EL; Knisely JP; Redmond K; Sohn JW; Machtay M; Sloan AE; Mansur DB; Rogers LR; Lo SS
    Expert Rev Anticancer Ther; 2015 May; 15(5):545-52. PubMed ID: 25907706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
    Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
    Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.